MwanzoAXGN • NASDAQ
add
AxoGen, Inc Common Stock
$ 16.16
Baada ya Saa za Kazi:(0.00%)0.00
$ 16.16
Imefungwa: 24 Apr, 16:02:16 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 15.62
Bei za siku
$ 15.58 - $ 16.43
Bei za mwaka
$ 5.56 - $ 21.00
Thamani ya kampuni katika soko
716.60M USD
Wastani wa hisa zilizouzwa
elfu 489.41
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 49.40M | 15.10% |
Matumizi ya uendeshaji wa biashara | 35.56M | 0.97% |
Mapato halisi | elfu 450.00 | 111.56% |
Kiwango cha faida halisi | 0.91 | 110.03% |
Mapato kwa kila hisa | 0.07 | 216.67% |
EBITDA | 3.72M | 335.76% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 33.48M | 7.92% |
Jumla ya mali | 203.73M | 3.51% |
Jumla ya dhima | 99.82M | -1.33% |
Jumla ya hisa | 103.91M | — |
hisa zilizosalia | 44.34M | — |
Uwiano wa bei na thamani | 6.65 | — |
Faida inayotokana na mali | 2.55% | — |
Faida inayotokana mtaji | 2.92% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | elfu 450.00 | 111.56% |
Pesa kutokana na shughuli | 8.74M | 4,239.81% |
Pesa kutokana na uwekezaji | elfu -813.00 | -193.50% |
Pesa kutokana na ufadhili | elfu 970.00 | 132.06% |
Mabadiliko halisi ya pesa taslimu | 8.89M | 12,802.86% |
Mtiririko huru wa pesa | 7.99M | 2,626.85% |
Kuhusu
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Ilianzishwa
2002
Makao Makuu
Tovuti
Wafanyakazi
452
